As we observe Breast Cancer Awareness Month (October), Cabrini continues its relentless pursuit in the fight against this pervasive disease. Through groundbreaking clinical trials and a commitment to advancing patient care, Cabrini is actively contributing to reshaping breast cancer treatment and improving survival rates.

Associate Professor Yoland Antill, one of Cabrini’s leading researchers, emphasises the critical role of clinical trials in developing new treatments. Prof Antill explains, “It takes a brave participant. It is experimental, might not work, and might be associated with increased side effects. But each trial we have in the phase three study is there on the basis of a hypothesis that it will be a successful new treatment.” This bravery is truly inspiring and is a testament to the human spirit in the face of adversity.

One such trial that has recently changed the standard of care worldwide is the Keynote 522 study, in which Cabrini actively contributed participants. This groundbreaking research, which investigated the addition of pembrolizumab, an immunotherapy drug, to chemotherapy for women with high-risk, triple-negative breast cancer, has had a profound impact. The results have been nothing short of remarkable, offering hope for the future of breast cancer treatment.

“Keynote 522 proved to both improve the likelihood of pathological complete response and to improve the likelihood of surviving that diagnosis of breast cancer,” Prof Antill states. This means that patients treated with this combination therapy have a better chance of eliminating all detectable cancer before surgery and a lower risk of relapse, ultimately improving their quality of life and overall survival.

Prof Antill shared the story of one of her patients, Kylie Pardo, who participated in the Keynote 522 trial. Kylie completed her treatment just under 12 months since diagnosis and has since had another baby, who is now three years old. Read Kylie’s full story.

As we reflect on the progress made and the challenges ahead this Breast Cancer Awareness Month, we should remind ourselves of the power of research, collaboration, and the bravery of patients participating in clinical trials. Their contributions are paving the way for better treatments, improved survival rates, and, ultimately, a future where breast cancer may be more effectively managed or even prevented. Read the Herald Sun article.

Cabrini acknowledges and is deeply grateful to our generous Cabrini Foundation donors, whose invaluable support makes these life-changing trials possible. They truly make a difference, enabling Cabrini to advance medical research and improve patient care.

Learn more about Cabrini Breast Cancer Care services, including trials.